Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application Number 10/625,103 **TRANSMITTAL** Filing Date July 22, 2003 **FORM** First Named Inventor Bailon Art Unit (to be used for all correspondence after initial filing) 1654 **Examiner Name** Heard, Thomas S. Attorney Docket Number 21327 US2 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Identify below): Extension of Time Request Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) International Search Report; Written Opinion; References Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Samuel H. Megerditchian Individual Signature Date June 21, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date June 21, 2005

Typed or printed Samuel H. Megerditchian June 21, 2005 Date Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Pascal S. Bailon, Chee-Youb Won

Serial No. 10/625,103, filed July 22, 2003

Docket No. 21327 US2

For: PEGYLATED T1249 POLYPEPTIDE

# REQUEST TO CHARGE DEPOSIT ACCOUNT

Nutley, New Jersey 07110 June 21, 2005

Mail Stop: Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an **INFORMATION DISCLOSURE STATEMENT** in the above-identified application.

- <u>X</u> Please charge Deposit Account No. 08-2525 in the amount of \$180.00 which is the fee in connection with the filing of the enclosed paper.
- <u>X</u> The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525.

DEPOSIT ACCOUNT NO. 08-2525

OUR ORDER NO. <u>6160</u>

Serial No. 10/625,103 Filed: July 22, 2003

> <u>X</u> This sheet is provided in duplicate.

> > Respectfully submitted,

Attorney of Record Samuel H. Megerditchian

(Reg. No. 45,678)

Telephone: (973) 235-4391 Telefax: (973) 235-2363

158257

A,





#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

; Inventor(s) Bailon, et. al. Group: 1654

Serial No. 10/625,103, filed July 22, 2003

Docket No. 21327 US2

Examiner: Heard, Thomas S.

For: PEGYLATED T1249 POLYPEPTIDE

### INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 June 21, 2005

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir: 😘

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A11 - A12 and C3 - C4 are listed on Form PTO-1449. Documents C3 - C4 are enclosed. Documents A11 - A12 are not being submitted because they are U.S. Patents.

Enclosed is a Written Opinion, dated April 1, 2005, which was issued by the European Patent Office in the International Application No. PCT/EP 0307711, filed July 16, 2003. The Written Opinion lists Document A9, which was cited in an Information Disclosure Statement dated October 17, 2003, and also lists Document C4, which is enclosed.

06/24/2005 MWOLDGE1 00000019 082525 10625103

01 FC:1806

180.00 DA

Serial No. 10/625,103

Filed: July 22, 2003

Also enclosed is a list of all references that have been cited by Patent Offices which lists Documents A11 – A12 and C3. Document C3 is enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted after the first Office Action on the merits and after three months of the filing date for the captioned application, there is enclosed a Fee Sheet.

Respectfully submitted,

Attorney for Applicant(s)
Samuel H. Megerditchian

(Reg. No. 45,678) 340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-4391

Telefax: (973) 235-2363

158248

/	OIPE \	
	C103	١
<u>\$</u>	JUN 2 3 2005 2	
LEF.	PADE DE CONTRACTOR	•

<u>\*</u>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(Use several sheets if necessary)

of 1

Compl	ete if Known
Application Number	10/625,103
Filing Date	July 22, 2003
First Name Inventor	Bailon
Group Art Unit	1654
Examiner Name	Heard, Thomas S.
Attorney Docket Number	21327 US2

Sheet **U.S. PATENT DOCUMENTS** U.S. Patent Document Name of Patentee or Applicant of Date of Publication of Examiner Cite Kind Code<sup>2</sup> Initials' No.1 Cited Document Cited document Number (if known) MM-DD-YYYY 2003/0125516 07-03-2003 A11 Bray, et. al. A12 5795569 Bartley, et. al. 08-18-1998

## **FOREIGN PATENT DOCUMENTS**

P	G:	Foreign Patent Document			N. CD-44-	Date of Publication of	T <sub>e</sub>
Examiner Initials'	Cite No.1	Office <sup>3</sup>	Number 1	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
1.							
	,						
•							
Examiner		Date Co	onsidered				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

			Substitute f	or form 1449A/PTO	Comple	ete if Known
	OIP	NEORMA	TION	DISCLOSURE Y APPLICANT	Application Number	10/625,103
/	10.75	<b>ЯА</b> ТЕМІ	ENT B	Y APPLICANT	Filing Date	July 22, 2003
		<b>છ</b> ∖			First Name Inventor	Bailon
,	UN 2 3	2005 (Get sev	eral shee	ets if necessary)	Group Art Unit	1654
		<u> </u>			Examiner Name	Heard, Thomas S
<u>ک</u> .	Sheet	2 🕏	Of	2	Attorney Docket Number	21327 US2
V	<b>EADENE</b>	air is	, -, -, -, -	NON DATENT	LITEDATUDE DOCUMENTS	

CE INIT		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	$T^2$
Initials'	No.1	of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	
	C3	Contrled-Release, Pegylation, Liposomal Formulations: New	
	C3		
	1	Mechanism in the Delivery of Injectable Drugs (2000), Vol. 34,	
7.33		pp 915-923	
	C4	Biomaterials 22, p. 405-417 (2001) "Review-Peptide and	
		protein PEGylation"	
	+		
	+		
	+		
	<del> </del>		
	†		
	<del></del>		
ar day ar .			
	1		
	-		
<del></del>			
	<del>  -</del> -		
Examiner		DATE	
Signature		CONSIDERED	

Signature CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

\*158247.\*